🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing worldwide, with data suggesting in excess of 82 million infections each year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the context of rising global incidence, the spread of superbugs and the very limited therapeutic options presently on offer.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This authorization marks a significant shift in the treatment of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

According to findings released by a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which uses a dual-drug approach. The study enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the rights to register and commercialise the drug in numerous developing nations.

Doctors directly involved have shared hope. Access to a single-dose, oral treatment such as this is seen as a "game-changer" for public health efforts. This is viewed as essential to reduce the burden of the infection for individuals and to prevent the spread of untreatable gonorrhoea around the world.